Non-natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity
Overview
Authors
Affiliations
Nonpeptidic chiral macrocycles were designed on the basis of an analogue of suberoylanilide hydroxamic acid (2) (SAHA, vorinostat) and evaluated against 11 histone deacetylase (HDAC) isoforms. The identification of critical amino acid residues highly conserved in the cap region of HDACs guided the design of the suberoyl-based macrocycles, which were expected to bear a maximum common substructure required to target the whole HDAC panel. A nanomolar HDAC inhibitory profile was observed for several compounds, which was comparable, if not superior, to that of 2. A promising cytotoxic activity was found for selected macrocycles against lung and colon cancer cell lines. Further elaboration of selected candidates led to compounds with an improved selectivity against HDAC6 over the other isozymes. Pair-fitting analysis was used to compare one of the best candidates with the natural tetrapeptide apicidin, in an effort to define a general pharmacophore that might be useful in the design of surrogates of peptidic macrocycles as potent and isoform-selective inhibitors.
Das T, Khatun S, Jha T, Gayen S Mini Rev Med Chem. 2023; 24(7):767-784.
PMID: 37818566 DOI: 10.2174/0113895575267301230919165827.
Poonia P, Sharma M, Jha P, Chopra M Mol Divers. 2022; 27(5):2053-2071.
PMID: 36214962 DOI: 10.1007/s11030-022-10540-3.
Liang Y, Fang R, Rao Q Molecules. 2022; 27(9).
PMID: 35566196 PMC: 9100616. DOI: 10.3390/molecules27092837.
Selg C, Scholer A, Schliehe-Diecks J, Hanl M, Sinatra L, Borkhardt A Chem Sci. 2021; 12(35):11873-11881.
PMID: 34659728 PMC: 8442681. DOI: 10.1039/d1sc02268g.
Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors.
Kutil Z, Mikesova J, Zessin M, Meleshin M, Novakova Z, Alquicer G ACS Omega. 2019; 4(22):19895-19904.
PMID: 31788622 PMC: 6882135. DOI: 10.1021/acsomega.9b02808.